OIVD Creates Internal Adverse Events Database; CoA Requirements Rare
This article was originally published in The Gray Sheet
Executive Summary
FDA's in vitro diagnostics office recently established an in-house adverse events database to make a wider selection of post-approval information available to OIVD premarket review staff
You may also be interested in...
AdvaMed Comments On Device Center Condition-Of-Approval Study Plans
Manufacturers should begin working with FDA to develop postmarket study protocols early in the premarket process, according to CDRH Office of Surveillance & Biometrics Director Susan Gardner
MDUFMA Retains Center Stage In FY ’05, With Postmarket In Supporting Role
CDRH Director Dan Schultz, MD, plans to preserve the strategic framework his predecessor envisioned for the device center
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”